Jacobs Levy Equity Management
PTGX icon

Jacobs Levy Equity Management’s Protagonist Therapeutics PTGX Stock Holding History

Jacobs Levy Equity Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-128,654
Closed -$6.22M – 1145
2025
Q1 		$6.22M Hold
128,654
– – 0.02% 416
2024
Q4 		$4.97M Hold
128,654
– – 0.02% 434
2024
Q3 		$5.79M Sell
128,654
-357
-0.3% -$14.4K 0.02% 420
2024
Q2 		$4.47M Hold
129,011
– – 0.02% 475
2024
Q1 		$3.73M Hold
129,011
– – 0.02% 482
2023
Q4 		$2.96M Hold
129,011
– – 0.01% 535
2023
Q3 		$2.15M Sell
129,011
-17,476
-12% -$339K 0.01% 551
2023
Q2 		$4.05M Sell
146,487
-74,504
-34% -$1.86M 0.02% 441
2023
Q1 		$5.08M Sell
220,991
-63,124
-22% -$1.06M 0.03% 395
2022
Q4 		$3.1M Buy
284,115
+29,775
+12% +$251K 0.02% 474
2022
Q3 		$2.14M Buy
+254,340
New +$2.41M 0.02% 543
2020
Q3 		– Sell
-68,279
Closed -$1.21M – 1095
2020
Q2 		$1.21M Sell
68,279
-4,078
-6% -$51.2K 0.01% 636
2020
Q1 		$511K Sell
72,357
-19,474
-21% -$146K 0.01% 751
2019
Q4 		$647K Buy
91,831
+78,021
+565% +$775K 0.01% 752
2019
Q3 		$166K Buy
+13,810
New +$174K ﹤0.01% 861
2019
Q2 		– Sell
-21,700
Closed -$273K – 1010
2019
Q1 		$273K Sell
21,700
-6,700
-24% -$59.1K ﹤0.01% 851
2018
Q4 		$191K Buy
28,400
+1,900
+7% +$15.1K ﹤0.01% 892
2018
Q3 		$273K Buy
+26,500
New +$228K ﹤0.01% 878

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's PTGX Position: Q2 2025 in Review

Jacobs Levy Equity Management sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 128,654 shares — an estimated $6.22M sold.

Jacobs Levy Equity Management first reported a position in PTGX in Q3 2018 and held it in 18 quarters. The position peaked at $6.22M in Q1 2025. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Jacobs Levy Equity Management reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 128,654 Protagonist Therapeutics shares in Q2 2025, an estimated $6.22M.
  • Jacobs Levy Equity Management first reported a position in Protagonist Therapeutics in Q3 2018 and held it in 18 quarters.
  • Jacobs Levy Equity Management's Protagonist Therapeutics position peaked at $6.22M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2025, filed 14 Aug 2025.